Literature DB >> 23943852

Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals.

Liwen Zhang1, Dennis A Simpson, Cynthia L Innes, Jeff Chou, Pierre R Bushel, Richard S Paules, William K Kaufmann, Tong Zhou.   

Abstract

Ataxia telangiectasia (AT) is a rare autosomal recessive disease caused by mutations in the ataxia telangiectasia-mutated gene (ATM). AT carriers with one mutant ATM allele are usually not severely affected although they carry an increased risk of developing cancer. There has not been an easy and reliable diagnostic method to identify AT carriers. Cell cycle checkpoint functions upon ionizing radiation (IR)-induced DNA damage and gene expression signatures were analyzed in the current study to test for differential responses in human lymphoblastoid cell lines with different ATM genotypes. While both dose- and time-dependent G1 and G2 checkpoint functions were highly attenuated in ATM-/- cell lines, these functions were preserved in ATM+/- cell lines equivalent to ATM+/+ cell lines. However, gene expression signatures at both baseline (consisting of 203 probes) and post-IR treatment (consisting of 126 probes) were able to distinguish ATM+/- cell lines from ATM+/+ and ATM-/- cell lines. Gene ontology (GO) and pathway analysis of the genes in the baseline signature indicate that ATM function-related categories, DNA metabolism, cell cycle, cell death control, and the p53 signaling pathway, were overrepresented. The same analyses of the genes in the IR-responsive signature revealed that biological categories including response to DNA damage stimulus, p53 signaling, and cell cycle pathways were overrepresented, which again confirmed involvement of ATM functions. The results indicate that AT carriers who have unaffected G1 and G2 checkpoint functions can be distinguished from normal individuals and AT patients by expression signatures of genes related to ATM functions.

Entities:  

Keywords:  ataxia telangiectasia-mutated; gene expression signature; ionizing radiation

Mesh:

Year:  2013        PMID: 23943852      PMCID: PMC3798780          DOI: 10.1152/physiolgenomics.00064.2013

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  60 in total

Review 1.  The many substrates and functions of ATM.

Authors:  M B Kastan; D S Lim
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

2.  Identification of ataxia telangiectasia heterozygotes, a cancer-prone population, using the single-cell gel electrophoresis (Comet) assay.

Authors:  C S Djuzenova; D Schindler; H Stopper; H Hoehn; M Flentje; U Oppitz
Journal:  Lab Invest       Date:  1999-06       Impact factor: 5.662

3.  ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.

Authors:  D Pernin; J O Bay; N Uhrhammer; Y J Bignon
Journal:  Eur J Cancer       Date:  1999-07       Impact factor: 9.162

4.  Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice.

Authors:  C Barlow; M A Eckhaus; A A Schäffer; A Wynshaw-Boris
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

5.  Global analysis of ATM polymorphism reveals significant functional constraint.

Authors:  Y R Thorstenson; P Shen; V G Tusher; T L Wayne; R W Davis; G Chu; P J Oefner
Journal:  Am J Hum Genet       Date:  2001-07-03       Impact factor: 11.025

Review 6.  Cell cycle checkpoint signaling through the ATM and ATR kinases.

Authors:  R T Abraham
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

Review 7.  ATM and ATR: networking cellular responses to DNA damage.

Authors:  Y Shiloh
Journal:  Curr Opin Genet Dev       Date:  2001-02       Impact factor: 5.578

8.  Modest increased sensitivity to radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells.

Authors:  L B Smilenov; D J Brenner; E J Hall
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

9.  Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations.

Authors:  T Shigeta; M Takagi; D Delia; L Chessa; S Iwata; Y Kanke; M Asada; M Eguchi; S Mizutani
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

10.  Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity.

Authors:  S G Becker-Catania; G Chen; M J Hwang; Z Wang; X Sun; O Sanal; E Bernatowska-Matuszkiewicz; L Chessa; E Y Lee; R A Gatti
Journal:  Mol Genet Metab       Date:  2000-06       Impact factor: 4.797

View more
  1 in total

1.  Individual Radiosensitivity Assessment of the Families of Ataxia-Telangiectasia Patients by G2-Checkpoint Abrogation.

Authors:  Asghar Aghamohammadi; Seyed M Akrami; Marjan Yaghmaie; Nima Rezaei; Gholamreza Azizi; Mehdi Yaseri; Hassan Nosrati; Majid Zaki-Dizaji
Journal:  Sultan Qaboos Univ Med J       Date:  2019-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.